CompletedPhase 2

Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)

United States113 participantsStarted 2004-04

Plain-language summary

This is an open label, Phase 2 trial of APC8015F immunotherapy in men with objective disease progression on protocol D9902 part B (NCT00065442)

Who can participate

Age range18 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Objective disease progression * Subjects must have been enrolled in the APC-Placebo arm of D9902B (NCT00065442) Exclusion Criteria: * Infection requiring IV antibiotics * Treatment with anticancer interventions within 14 days prior to enrollment * Any medical condition which could compromise the study's objectives (discretion from sponsor)

What they're measuring

Safety of APC8015F by Review of Reported Adverse Events

Timeframe: periodically over 24 months

Trial details

NCT IDNCT00849290

SponsorDendreon

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2009-01

Results submitted2010-05-28

View on ClinicalTrials.gov More Metastatic Androgen Independent Prostate Cancer trials